{"id":"W2740310721","doi":"10.1158/1538-7445.am2017-ct098","title":"Abstract CT098: Phase 1 first-in-human study of anti-clusterin antibody AB-16B5 in patients with advanced solid malignancies","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alethia Biotherapeutics (Canada); Jewish General Hospital","funders":"","keywords":"Medicine; Tolerability; Clusterin; Cancer; Internal medicine; Sarcoma; Antibody; Oncology; Bone marrow; Urology; Cancer research; Pathology; Immunology; Adverse effect; Apoptosis; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00120403,0.001546891,0.001628432,0.0004907965,0.0004858767,0.0008651674,0.0009395159,0.0009989304,0.004814404],"category_scores_gemma":[0.0005499722,0.0005356792,0.0007650538,0.0004560902,0.0009145971,0.0004892878,0.0003609407,0.002612426,0.00144473],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0011781,"about_ca_system_score_gemma":0.002160041,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001685199,"about_ca_topic_score_gemma":0.003735701,"domain_scores_codex":[0.9995812,0.0002177758,0.0000169061,0.00005972597,0.00003710656,0.00008740486],"domain_scores_gemma":[0.9995334,0.00005355338,0.00006870786,0.00004522248,0.00003754174,0.0002615025],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5032106,0.1250241,0.01086763,0.00156382,0.00114949,0.00074888,0.0004121148,0.005045238,0.1996388,0.0006815268,0.01480106,0.1368568],"study_design_scores_gemma":[0.2764449,0.6843414,0.01430172,0.00006359016,0.0003365046,0.0006947814,0.00006764388,0.001488229,0.01411341,0.0002127688,0.007905441,0.0000296455],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9834498,0.002811748,0.001147285,0.0005841724,0.0001660098,0.005459044,0.003047115,0.0002366144,0.003098298],"genre_scores_gemma":[0.9791092,0.001787795,0.002823496,0.000829573,0.0001543894,0.004722511,0.00478427,0.00005486697,0.005733934],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004814404,"threshold_uncertainty_score":0.01610583,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07865060191518167,"score_gpt":0.4884078122763769,"score_spread":0.4097572103611953,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}